All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Camidanlumab Tesirine,Pembrolizumab
Therapeutic Area: Oncology Product Name: ADCT-301
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2020
Details:
First patient has been dosed with camidanlumab tesirine (Cami, formerly ADCT-301) in combination with pembrolizumab, a checkpoint inhibitor, in an ongoing Phase 1b clinical trial in patients with selected advanced solid tumors.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Camidanlumab Tesirine
Therapeutic Area: Oncology Product Name: ADCT-301
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
The ongoing, multicenter, open-label Phase 1b clinical trial of camidanlumab tesirine (Cami, formerly ADCT-301) is enrolling patients with selected locally advanced or metastatic solid tumors.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Minigastrin-Lu177
Therapeutic Area: Oncology Product Name: Debio 1124
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2020
Details:
First patient dosed in the multicenter, single-arm, open-label Phase 1 study assessing the safety, distribution, and dosing of Debio 1124 in patients with advanced, unresectable pulmonary and extrapulmonary small cell carcinoma.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Emactuzumab
Therapeutic Area: Oncology Product Name: RG7155
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Celleron
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 12, 2020
Details:
Roche to provid Celleron exclusive world-wide rights for the clinical development, manufacturing and commercialization of emactuzumab. Emactuzumab is a monoclonal antibody designed to target and deplete macrophages in the tumor tissue.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RO7198457,Atezolizumab
Therapeutic Area: Oncology Product Name: RO7198457
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
A phase 1b trial of a personalized cancer vaccine in development at Roche and BioNTech has chalked up a “low” response rate.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Glofitamab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2020
Details:
Results from the phase I NP30179 study show durable complete responses with glofitamab in patients with aggressive and indolent lymphomas after a median of three prior lines of therapy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): FAZ053
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Laekna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 24, 2020
Details:
Laekna now has exclusive rights to develop and commercialize the PD-L1 oncology asset. With this move, the company aims to advance clinical research and introduce pioneering new drugs to patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Debio 0123
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2020
Details:
Debio 0123 starts first-in-human, dose escalation phase I clinical trial assessing the safety and efficacy of the compound in combination with carboplatin to treat refractory solid tumors.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IOA-244
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2020
Details:
The phase I study will enrol approximately 60 patients with solid tumours that overexpress PI3K? and are burdened by immune cells of the suppressor phenotype that are sensitive to PI3K? inhibition.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IOA-244
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: INKEF Capital
Deal Size: $16.5 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 23, 2020
Details:
iOnctura will use the proceeds of the Series A to move its lead molecule IOA-244, a highly selective PI3K?-inhibitor, into a Phase I trial in solid tumours and its second program, IOA-289, an ATX-inhibitor, through IND enabling studies.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
